Investment Rating - The report maintains a "Buy" rating for the company [2] Core Views - The company achieved a significant increase in revenue and net profit in 2024, with operating income reaching 101.31 billion yuan, up 22.6% year-on-year, and net profit attributable to shareholders at 1.20 billion yuan, up 50.8% year-on-year [6] - The company is the largest polyester filament manufacturer in China and is expected to benefit from industry recovery and new capacity investments in regions like Fujian and Anhui [9] - The report anticipates a steady increase in net profit for 2025-2027, projecting net profits of 2.02 billion yuan, 2.99 billion yuan, and 3.41 billion yuan, respectively, with corresponding EPS of 0.84 yuan, 1.24 yuan, and 1.42 yuan [9] Financial Performance Summary - In Q4 2024, the company reported a revenue of 25.26 billion yuan, a year-on-year increase of 20.9%, and a net profit of 195 million yuan, up 283.2% year-on-year [6] - For Q1 2025, the company recorded a revenue of 19.42 billion yuan, down 8.0% year-on-year, but net profit increased by 5.4% year-on-year to 611 million yuan [6] - The company’s polyester production capacity is approximately 13 million tons per year, and it plans to add two new production lines in 2025, which are expected to enhance profit margins [6][9] Industry Outlook - The growth rate of polyester filament production capacity is expected to slow down, with a projected CAGR of 1.5% from 2024 to 2026, down from 7.1% from 2017 to 2023 [7] - The demand for polyester filament is projected to increase by 18% in 2024, with an absolute increment of nearly 5 million tons, indicating a positive market outlook [7] - The industry is undergoing consolidation, with the market share of the top six companies increasing from 48% in 2018 to 66% in 2023, suggesting a more favorable competitive environment for larger manufacturers [7]

[Table_Main] 证券研究报告 | 固定收益点评 2025 年 5 月 12 日 固定收益点评 证券分析师 吕品 资格编号：S0120524050005 邮箱：lvpin＠tebon.com.cn 严伶怡 资格编号：S0120524110003 邮箱：yanly＠tebon.com.cn 研究助理 货币资金面 请务必阅读正文之后的信息披露和法律声明 本周（5.6-5.9，下同）共有 16178 亿元逆回购到期。周二至周五央行分别投放逆 回购 4050、1955、1586、770 亿元，期间累计投放 8361 亿元逆回购，全周净回 笼流动性 7817 亿元。本周资金价格下行，截至 5 月 9 日，R001、R007、DR001、 DR007 分别为 1.52%、1.58%、1.49%、1.54%，较 4 月 30 日分别变动-33.21BP、 -25.91BP、-29.45BP、-25.77BP，分别位于 22%、9%、20%、3%历史分位数。 本周资金主要融出方净融入规模减少。本周资金主要融出方净融入规模减少。主要 融出机构（大行/政策行与股份行）全周（5.6-5.9）净融入-4639 亿元，与前一周 ...

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [1]. Core Views - The company is a leader in IT operations monitoring and observability in China, with a focus on upgrading its main business and enhancing profitability through new product launches [5][9]. - The new product, Bonree ONE, is expected to enter a growth phase, benefiting from partnerships with Huawei and ByteDance [5][9]. - The company has shown signs of revenue stabilization and growth, with projected revenues increasing significantly in the coming years [5][9]. Summary by Sections 1. Company Overview - The company is the first A-share listed firm in the application performance monitoring and observability (APMO) sector in China, holding a market share of 19.8% as of H2 2024 [5][9]. - It has a strong technical foundation with numerous patents and software copyrights, indicating its advanced technological capabilities [9][19]. 2. Business Performance - The company experienced a decline in revenue and profit due to macroeconomic fluctuations and market competition in recent years, but has shown signs of recovery since 2023 with the launch of Bonree ONE [5][26]. - In 2024, the company achieved revenue of 141 million yuan, a year-on-year increase of 16.4% [5][26]. - The company’s net profit for 2024 was -115 million yuan, a decrease of 8% compared to the previous year, but the first quarter of 2025 showed a narrowing of losses [5][26]. 3. Product Development - Bonree ONE represents a significant upgrade from previous products, integrating various monitoring capabilities and utilizing AI technology for enhanced data analysis [5][13]. - The product is designed to be compatible with heterogeneous computing environments, addressing the growing demand for cloud computing and AI applications [5][13]. 4. Market Position and Growth Potential - The company is positioned to benefit from the increasing demand for IT observability solutions driven by digital transformation and the complexity of IT systems [5][40]. - The APM market in China is expected to grow significantly, with the company poised to capture a larger share due to its innovative products and strategic partnerships [5][50]. 5. Financial Projections - Revenue forecasts for 2025-2027 are projected at 172 million, 234 million, and 301 million yuan, respectively, with significant year-on-year growth rates [5][26]. - The company aims to achieve profitability by 2025, with net profits expected to improve substantially in the following years [5][26].

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [1]. Core Views - The company is a leader in IT operations monitoring and observability in China, with a focus on upgrading its main business and enhancing profitability through new product launches [5][9]. - The new product, Bonree ONE, is expected to enter a growth phase, benefiting from partnerships with major players like Huawei and ByteDance [5][9]. - The company has shown signs of revenue stabilization and growth, with projected revenues increasing significantly in the coming years [5][9]. Summary by Sections 1. Company Overview - The company is the first A-share listed firm in the application performance monitoring and observability (APMO) sector in China, holding a 19.8% market share as of H2 2024 [5][9]. - It has a strong technical foundation with numerous patents and software copyrights, enhancing its competitive edge [9][19]. 2. Business Performance - Revenue for 2024 is projected at 141 million yuan, a year-on-year increase of 16.4% [5][4]. - The company has experienced a decline in net profit in recent years but is expected to narrow losses significantly in 2025 [5][4]. 3. Product Development - Bonree ONE represents a significant upgrade from previous products, integrating various monitoring capabilities and utilizing AI for enhanced data analysis [5][9]. - The product is designed to meet the increasing demand for unified monitoring solutions due to the growing complexity of IT systems [5][40]. 4. Market Trends - The demand for APM solutions is expected to grow as digital transformation accelerates and IT environments become more complex [5][40]. - The global data volume is projected to increase significantly, driving the need for advanced monitoring and observability solutions [5][41]. 5. Financial Projections - Revenue forecasts for 2025-2027 are 172 million, 234 million, and 301 million yuan, respectively, with significant year-on-year growth rates [5][4]. - The company aims to achieve profitability by 2025, with net profit projections showing a substantial recovery [5][4].

[Table_Main] 海外市场周报 证券分析师 薛威 资格编号：S0120523080002 邮箱：xuewei＠tebon.com.cn 谭诗吟 资格编号：S0120523070007 邮箱：tansy＠tebon.com.cn 证券研究报告 | 海外市场周报 2025 年 05 月 11 日 静待破局 [Table_Summary] 投资要点： 请务必阅读正文之后的信息披露和法律声明 上周全球股市涨跌参半。越南 VN30 指数领涨全球主要市场。美股三大指数集体回 调，道指、纳指和标普 500 涨跌幅分别为-0.2%、-0.3%和-0.5%；欧洲市场三大主 要指数表现分化，德国 DAX 指数上涨 1.8%，法国 CAC40 和英国富时 100 指数 小幅回调；亚太地区涨多跌少，仅恒生科技和印度 SENSEX30 指数回调。 美英协议的标杆作用大于实际意义。北京时间 5 月 8 日晚间，特朗普公布了美英 经贸谈判达成的协议一般条款，英国也成为了 4 月初全球"关税战"后首个与美国 达成经贸协议的国家。从大体内容上看，有三点值得重视：第一，基础关税 10% 得到保留，这也是 4 月初美国公布的对各国加征关税 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [2]. Core Insights - The report highlights a significant rebound in the stock prices of leading US healthcare AI companies, with Tempus and Grail both experiencing a 65% increase over the past month. This sector is noted for its rapid implementation and growing investor interest [8][10]. - It suggests focusing on domestic companies that are likely to benefit from the overseas AI healthcare performance, specifically mentioning companies like RunDa Medical and YiMaiTong as having strong potential for AI-driven revenue growth [5][10]. Summary by Sections 1. Focus on US AI Leaders and Domestic Opportunities - The report emphasizes the recent stock price rebounds of US healthcare AI leaders, with notable increases of 65% for Tempus and Grail, and suggests that AI in healthcare is one of the fastest-growing fields [8]. - It recommends monitoring companies such as RunDa Medical, YiMaiTong, and others that are expected to achieve rapid AI performance growth [10]. 2. Weekly Market Review and Hotspot Tracking (May 6 - May 9, 2025) - The report notes that the Shenwan Pharmaceutical and Biotechnology Index rose by 1.01% during the week, underperforming the CSI 300 Index by 1.0%. Year-to-date, the index has increased by 1.19%, outperforming the CSI 300 by 3.44% [32]. - The top five performing stocks during this period included Changshan Pharmaceutical (up 23.59%), Xiangxue Pharmaceutical (up 19.64%), and others [44]. 3. Company Highlights - RunDa Medical has established deep collaborations with Huawei for AI applications across various healthcare settings, providing digital solutions to over 80 hospitals by the end of 2024 [12][13]. - YiMaiTong, a leading online professional physician platform, has seen its registered physician count grow from 228,000 in 2018 to 867,000 in 2024, with a compound annual growth rate (CAGR) of 24.9% [17][20]. The company’s revenue increased from 83.46 million yuan to 558.46 million yuan from 2018 to 2024, reflecting a CAGR of 37.3% [20]. 4. Monthly Investment Portfolio - The report lists a monthly investment portfolio that includes companies such as Kangfang Biotech, Zai Lab, and others, indicating a focus on innovative drugs and companies with emerging performance [5]. 5. Market Valuation and Trading Volume - As of May 9, 2025, the overall valuation of the Shenwan Pharmaceutical sector was 32.3, with a slight increase from the previous week [38]. The total trading volume for the sector reached 287.2 billion yuan, accounting for 5.3% of the total A-share trading volume [40].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [2]. Core Insights - The report highlights a significant rebound in the stock prices of leading US healthcare AI companies, with Tempus and Grail both experiencing a 65% increase over the past month. This sector is noted for its rapid implementation and growing investor interest [8][10]. - It suggests focusing on domestic companies that can mirror the growth of these US AI leaders, particularly those like RunDa Medical and YiMaiTong, which are positioned to leverage AI for substantial performance gains [10][12]. Summary by Sections 1. Focus on US AI Leaders and Domestic Opportunities - The report emphasizes the recent stock price rebounds of US healthcare AI leaders, with notable increases of 65% for Tempus and Grail, and suggests that AI in healthcare is one of the fastest-growing fields [8]. - It recommends monitoring domestic companies such as RunDa Medical and YiMaiTong for potential investment opportunities as they implement AI solutions [10][12]. 2. Weekly Market Review and Hotspot Tracking (May 6 - May 9, 2025) - The report notes that the Shenwan Pharmaceutical and Biotechnology Index rose by 1.01% during the week, underperforming the CSI 300 Index by 1.0%. Year-to-date, the index has increased by 1.19%, outperforming the CSI 300 by 3.44% [32]. - The top-performing stocks during this period included Changshan Pharmaceutical (up 23.59%) and Xiangxue Pharmaceutical (up 19.64%) [44]. 3. Company Highlights - RunDa Medical has established deep collaborations with Huawei to implement AI solutions across over 80 hospitals, enhancing its digital healthcare offerings [12][13]. - YiMaiTong, a leading online professional physician platform in China, has seen its registered physician count grow to over 4 million, with a compound annual growth rate (CAGR) of 24.9% in paid clicks from 2018 to 2024 [17][20]. 4. Monthly Investment Portfolio - The report lists a monthly investment portfolio that includes companies such as Kangfang Biotech, Zai Lab, and Titan Technologies, indicating a focus on firms with strong fundamentals and growth potential [5].

Investment Rating - The report maintains an "Outperform" rating for the basic chemical industry [2] Core Viewpoints - The basic chemical sector has outperformed the market, with the industry index rising by 2.1% from April 30 to May 9, 2025, compared to a 1.9% increase in the Shanghai Composite Index [6][17] - The report highlights the widening price gap between domestic and international nitrogen and phosphorus fertilizers, indicating potential export opportunities [6][27] - The domestic urea production is projected to reach 67.54 million tons in 2024, with a supply surplus expected due to limited export policies [28] - The report suggests that the chemical industry may enter a new long-term prosperity cycle, driven by recent policy changes and supply-side reforms [14][15] Summary by Sections 1. Core Viewpoints - The report emphasizes that the chemical industry is likely to benefit from recent government policies aimed at boosting demand and stabilizing the economy [14] - It identifies four main investment themes: core assets entering a long-term value zone, industries with supply constraints showing elasticity, demand certainty in specific sectors, and high-dividend resource stocks [15] 2. Overall Performance of the Chemical Sector - The basic chemical industry index has shown a year-to-date increase of 3.3%, outperforming both the Shanghai Composite and ChiNext indices [17][21] 3. Individual Stock Performance in the Chemical Sector - Among 424 stocks in the basic chemical sector, 364 stocks rose, with notable gainers including Heng Tian Hai Long (+23.6%) and Yu San Xia A (+23.2%) [25][26] 4. Key News and Company Announcements - A meeting was held by the National Development and Reform Commission to discuss the export of fertilizers, emphasizing a principle of prioritizing domestic supply while allowing for controlled exports [27] - The report notes significant price differences for urea and phosphate fertilizers between domestic and international markets, suggesting potential for increased exports if policies change [28]

煤炭 优于大市（维持） 证券分析师 翟堃 资格编号：s0120523050002 邮箱：zhaikun＠tebon.com.cn 研究助理 谢佶圆 邮箱：xiejy＠tebon.com.cn 市场表现 -34% -26% -17% -9% 0% 9% 17% 26% 2024-05 2024-09 2025-01 煤炭开采 沪深300 资料来源：聚源数据、德邦研究所 相关研究 1.《永泰能源（600157.SH）：煤炭 主业以量补价，煤电协同稳步推 进》，2025.4.29 2.《煤炭周报：宏观预期强化，重 视板块底部布局》，2025.4.27 3.《煤炭周报：煤价震荡寻底，关 注板块红利属性》，2025.4.20 4.《煤炭行业月报：3 月进口同比转 负 ， 静 待 后 续 需 求 改 善 》， 2025.4.18 5.《煤炭周报：煤价底部企稳，回 购增持彰显板块价值》，2025.4.12 煤炭周报: 板块业绩有望筑底， 寻找相对确定性机会 [Table_Summary] 投资要点： 煤炭开采 2025 年 05 月 11 日 请务必阅读正文之后的信息披露和法律声明 证券研究报告 | 行业周报 25Q1 业 ...

煤炭 优于大市（维持） 证券分析师 翟堃 资格编号：s0120523050002 邮箱：zhaikun＠tebon.com.cn 研究助理 谢佶圆 邮箱：xiejy＠tebon.com.cn 市场表现 -34% -26% -17% -9% 0% 9% 17% 26% 2024-05 2024-09 2025-01 煤炭开采 沪深300 资料来源：聚源数据、德邦研究所 相关研究 1.《永泰能源（600157.SH）：煤炭 主业以量补价，煤电协同稳步推 进》，2025.4.29 2.《煤炭周报：宏观预期强化，重 视板块底部布局》，2025.4.27 3.《煤炭周报：煤价震荡寻底，关 注板块红利属性》，2025.4.20 4.《煤炭行业月报：3 月进口同比转 负 ， 静 待 后 续 需 求 改 善 》， 2025.4.18 5.《煤炭周报：煤价底部企稳，回 购增持彰显板块价值》，2025.4.12 煤炭开采 2025 年 05 月 11 日 请务必阅读正文之后的信息披露和法律声明 证券研究报告 | 行业周报 25Q1 业绩同环比下滑，寻找相对确定性投资机会。据 CCTD 中国煤炭市场网， 2024 年煤炭全行业实现 ...